ALOX12 in human toxoplasmosis

Infection and Immunity

Volumn 82, Issue 7, 2014, Pages 2670-2679

  Witola, William H ^a   Liu, Susan Ruosu ^a   Montpetit, Alexandre ^b   Welti, Ruth ^c   Hypolite, Magali ^a,d   Roth, Mary ^c   Zhou, Ying ^a   Mui, Ernest ^a   Cesbron Delauw, Marie France ^d   Fournie, Gilbert J ^e   Cavailles, Pierre ^d   Bisanz, Cordelia ^d   Boyer, Kenneth ^a,f   Withers, Shawn ^a   Gwendolyn Noble, A ^a,g   Swisher, Charles N ^a,g   Heydemann, Peter T ^a,f   Rabiah, Peter ^a,h   Muench, Stephen P ⁱ   McLeod, Rima ^a,j  

^a UNIVERSITY OF CHICAGO   (United States)

^b MCGILL UNIVERSITY   (Canada)

^c KANSAS STATE UNIVERSITY   (United States)

^d CNRS   (France)

^e UNIVERSITÉ DE TOULOUSE   (France)

^f RUSH UNIVERSITY   (United States)

^g CHILDREN'S MEMORIAL HOSPITAL   (United States)

^h NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

ⁱ UNIVERSITY OF LEEDS   (United Kingdom)

^j UNIVERSITY OF CHICAGO   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONATE 12 LIPOXYGENASE;

ALLELE; ARTICLE; ATHEROSCLEROSIS; CATECHOLAMINE SYNTHESIS; CELL DEATH; CELL LINE; INFLAMMATION; LENTIVIRINAE; NEOPLASM; NONHUMAN; PARASITE LOAD; PRIORITY JOURNAL; RNA INTERFERENCE; SCHIZOPHRENIA; TOXOPLASMA GONDII; TOXOPLASMOSIS; VASOCONSTRICTION;

ALLELES; ARACHIDONATE 12-LIPOXYGENASE; ARACHIDONIC ACID; CASPASE 1; CELL LINE; COHORT STUDIES; CYTOKINES; FEMALE; GENE KNOCKDOWN TECHNIQUES; GENETIC VARIATION; HUMANS; MALE; MONOCYTES; PLASMIDS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TOXOPLASMOSIS, CONGENITAL;

EID: 84903159695     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01505-13     Document Type: Article

References (23)

1. McLeod R, van Tubbergen C, Montoya JG, Petersen E. 2013. Human Toxoplasma infection and toxoplasmosis, p 100-147. In Weiss LM, Kim K (ed), Toxoplasma gondii: the model apicomplexan: perspectives and methods, 2nd ed. Academic Press, Waltham, MA.
2. Roizen N, Swisher C, Stein M, Hopkins J, Boyer K, Patel D, Stein M, Schey W, Meier P, Mets M, Beckman J, McLeod R. 1995. Neurologic and developmental outcome in treated congenital toxoplasmosis. Pediatrics 95:11-20.
3. Cavaillès P, Bisanz C, Papapietro O, Colacios C, Sergent V, Pipy B, Saoudi A, Cesbron-Delauw M-F, Fournié GJ. 2006. The rat Toxo1 locus controls the outcome of the toxoplasmic infection according to a Mendelian mode. Med. Sci. (Paris) 22:679-680. (In French.). http://dx.doi.org/10.1051/medsci/20062289679.
4. Cavaillès P, Sergent V, Bisanz C, Papapietro O, Colacios C, Mas M, Subra JF, Lagrange DD, Calise MM, Appolinaire SS, Faraut TT, Druet PP, Saoudi AA, Bessieres MH, Pipy B, Cesbron-Delauw MF, Fournié GJ. 2006. The rat Toxo1 locus directs toxoplasmosis outcome and controls parasite proliferation and spreading by macrophage-dependent mechanisms. Proc. Natl. Acad. Sci. U. S. A. 103:744-749. http://dx.doi.org/10.1073/pnas.0506643103.
5. Anderson SE, Remington JS. 1974. Effect of normal and activated human macrophages on Toxoplasma gondii. J. Exp. Med. 139:1154-1174. http://dx.doi.org/10.1084/jem.139.5.1154.
6. Brash AR. 2001. Arachidonic acid as a bioactive molecule. J. Clin. Invest. 107:1339-1345. http://dx.doi.org/10.1172/JCI13210.
7. Lacape G, Daret D, Crockett R, Rigaud M, Larrue J. 1992. Dual metabolic pathways of 12-HETE in rat aortic smooth muscle cells. Prostaglandins 44:167-176.
8. Phillis JW, Horrocks LA, Farooqui AA. 2006. Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders. Brain Res. Rev. 52:201-243. http://dx.doi.org/10.1016/j.brainresrev.2006.02.002.
9. Jamieson SE, de Roubaix LA, Cortina-Borja MM, Tan HK, Mui E, Cordell HJ, Kirisits MJ, Miller EN, Peacock CS, Hargrave AC, Coyne JJ, Boyer K, Bessieres MH, Buffolano W, Ferret N, Franck J, Kieffer F, Meier P, Nowakowska DE, Paul M, Peyron F, Stray-Pedersen B, Prusa AR, Thulliez P, Wallon M, Petersen E, McLeod R, Gilbert RE, Blackwell JM. 2008. Genetic and epigenetic factors at COL2A1 and ABCA4 influence clinical outcome in congenital toxoplasmosis. PLoS One 3:e2285. http://dx.doi.org/10.1371/journal.pone.0002285.
10. Witola WH, Mui E, Hargrave A, Liu S, Hypolite M, Montpetit A, Cavailles P, Bisanz C, Cesbron-Delauw M-F, Fournié GJ, McLeod R. 2011. NALP1 influences susceptibility to human congenital toxoplasmosis, proinflammatory cytokine response, and fate of Toxoplasma gondiiinfected monocytic cells. Infect. Immun. 79:756-766. http://dx.doi.org/10.1128/IAI.00898-10.
11. Invitrogen. 29 June 2004. Gateway-adapted, lentiviral destination vector for high-level, regulated expression of shRNA in dividing and nondividing mammalian cells: user's manual. Invitrogen, Carlsbad, CA.
12. Invitrogen. 21 June 2007. Gateway-adapted entry vector for regulated expression of shRNA in mammalian cells: user's manual. Invitrogen, Carlsbad, CA.
13. Invitrogen. 29 September 2004. BLOCK-iT inducible H1 lentiviral RNAi system. Invitrogen, Carlsbad, CA.
14. Maccarrone M, Melino G, Finazzi-Agro A. 2001. Lipoxygenases and their involvement in programmed cell death. Cell Death Differ. 8:776-784. http://dx.doi.org/10.1038/sj.cdd.4400908.
15. Li J, Wang H, Rosenberg PA. 2009. Vitamin K prevents oxidative cell death by inhibiting activation of 12-lipoxygenase in developing oligodendrocytes. J. Neurosci. Res. 87:1997-2005. http://dx.doi.org/10.1002/jnr.22029.
16. Nazarewicz RR, Zenebe WJ, Parihar A, Parihar MS, Vaccaro M, Rink C, Sen CK, Ghafourifar P. 2007. 12(S)-Hydroperoxyeicosatetraenoic acid (12-HETE) increases mitochondrial nitric oxide by increasing intramitochondrial calcium. Arch. Biochem. Biophys. 468:114-120. http://dx.doi.org/10.1016/j.abb.2007.09.018.
17. Chen M, Yang ZD, Smith KM, Carter JD, Nadler JL. 2005. Activation of 12-lipoxygenase in proinflammatory cytokine-mediated beta cell toxicity. Diabetologia 48:486-495. http://dx.doi.org/10.1007/s00125-005-1673-y.
18. Ma K, Nunemaker CS, Wu R, Chakrabarti SK, Taylor-Fishwick DA, Nadler JL. 2010. 12-Lipoxygenase products reduce insulin secretion and β-cell viability in human islets. J. Clin. Endocrinol. Metab. 95:887-893. http://dx.doi.org/10.1210/jc.2009-1102.
19. Wen Y, Gu J, Vandenhoff GE, Liu X, Nadler JL. 2008. Role of 12/15-lipoxygenase in the expression of MCP-1 in mouse macrophages. Am J. Physiol. Heart Circ. Physiol. 294:H1933-H1938. http://dx.doi.org/10.1152/ajpheart.00260.2007.
20. Reynaud D, Pace-Asciak CR. 1997. 12-HETE and 12-HPETE potently stimulate intracellular release of calcium in intact human neutrophils. Prostaglandins Leukot. Essent. Fatty Acids 56:9-12. http://dx.doi.org/10.1016/S0952-3278(97)90518-4.
21. Tschopp J, Martinon F, Burns K. 2003. NALPs: a novel protein family involved in inflammation. Nat. Rev. Mol. Cell Biol. 4:95-104. http://dx.doi.org/10.1038/nrm1019.
22. Bleich D, Chen S, Gu JL, Thomas L, Scott S, Gonzales N, Natarajan R, Nadler JL. 1995. Interleukin-1β regulates the expression of a leukocyte type of 12-lipoxygenase in rat islets and RIN m5F cells. Endocrinology 136:5736-5744. http://dx.doi.org/10.1210/endo.136.12.7588331.
23. Yong EC, Chi EY, Henderson WR, Jr. 1994. Toxoplasma gondii alters eicosanoid release by human mononuclear phagocytes: role of leukotrienes in interferon gamma-induced antitoxoplasma activity. J. Exp. Med. 180:1637-1648. http://dx.doi.org/10.1084/jem.180.5.1637.